XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of Revenues
The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):
 Three Months Ended
September 30, 2024		Three Months Ended
September 30, 2023
 U.S.Non U.S.TotalU.S.Non U.S.Total
Product revenue, net     
HEPLISAV-B$79,345 $- $79,345 $62,318 $- $62,318 
Total product revenue, net79,345 - 79,345 62,318 - 62,318 
Other revenue1,263 22 1,285 7,196 - 7,196 
Total revenues$80,608 $22 $80,630 $69,514 $- $69,514 
      
 Nine Months Ended
September 30, 2024		Nine Months Ended
September 30, 2023
 U.S.Non U.S.TotalU.S.Non U.S.Total
Product revenue, net     
HEPLISAV-B$195,030 $2,347 $197,377 $162,209 $- $162,209 
Total product revenue, net195,030 2,347 197,377 162,209 - 162,209 
Other revenue7,663 174 7,837 14,479 - 14,479 
Total revenues$202,693 $2,521 $205,214 $176,688 $- $176,688 
Revenues from Major Customers and Collaboration Partners
All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include integrated delivery networks, retail pharmacies, independent hospitals and clinics, public health clinics and prisons, the Department of Defense, and the Department of Veterans Affairs. All of our HEPLISAV-B sales in Germany are to one distributor.
The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2024202320242023
Largest customer31 %27 %29 %25 %
Second largest customer20 %25 %21 %24 %
Third largest customer19 %18 %18 %17 %
Contract Balances
The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories for the nine months ended September 30, 2024 (in thousands):
 
Balance at
Beginning
of Period
Provisions
related to
current
period sales
Credit or
payments
made during
the period
Adjustments related to prior periods
Balance
at End of
Period
Nine months ended September 30, 2024:
Accounts receivable reserves (1)
$7,011 $57,494 $(53,716)$(10)$10,779 
Revenue reserve accruals (2)
$21,004 $43,507 $(32,385)$(871)$31,255 
(1)Reserves are for chargebacks, discounts and other fees.
(2)Accruals are for returns, rebates and other fees.
When we perform services under our agreement with the DoD, we recognize product revenue and a corresponding contract asset as our right to consideration is conditioned on something other than the passage of time. See Note 6 for further discussion. The following table summarizes balances and activities in our contract asset account (in thousands):
 
Balance at
Beginning
of Period
Additions
Subtractions
Balance
at End of
Period
Nine months ended September 30, 2024
Contract asset, included in other current assets (1)
$1,389 $7,663 $(8,314)$738 
Contract asset, included in other assets (long term) (2)
$71,307 $- $- $71,307 
(1)The $0.7 million of contract asset is derived from our agreement with the DoD.
(2)The Clover contract asset was included in long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 6 for further discussion.